QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

PTCT

QT82PTC Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
78.98
+0.45+0.57%
OverviewShort InterestFilings
PTCTQT82PTC Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
78.98+0.57%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-2.33
Insider Own1.78%
Shs Outstand82.95M
Perf Week5.72%
Market Cap6.51BForward P/E31.62EPS next Y2.50Insider Trans-0.15%Shs Float-Perf Month12.33%
Enterprise Value6.08BPEG0.27EPS next Q0.32Inst Own-Short Float-Perf Quarter17.74%
Income-187603446.00P/S7.88EPS this Y138.03%Inst Trans-Short Ratio-Perf Half Y4.72%
Sales827.11MP/B-EPS next Y181.89%ROA-6.51%Short Interest-Perf YTD3.98%
Book/sh-2.17P/C-EPS next 5Y56.25%ROE99.84%52W High87.50 -9.74%Perf Year55.32%
Cash/sh22.81P/FCF-EPS past 3/5Y-ROIC-2.38%52W Low43.18 82.91%Perf 3Y-
Dividend Est.-EV/EBITDA-50.81Sales past 3/5Y35.29% 35.36%Gross Margin77.84%Volatility4.08% 3.00%Perf 5Y-
Dividend TTM-EV/Sales7.34EPS Y/Y TTM50.74%Oper. Margin-8.18%ATR (14)3.28Perf 10Y-
Dividend Ex-Date-Quick Ratio2.36Sales Y/Y TTM2.60%Profit Margin-22.58%RSI (14)63.67Recom2.38
Dividend Gr. 3/5Y-Current Ratio2.44EPS Q/Q-100.30%SMA208.98%Beta0.85Target Price95.83
Payout0.00%Debt/Eq-2.19Sales Q/Q-76.79%SMA5011.20%Rel Volume1.88Prev Close78.53
Employees939LT Debt/Eq-0.93EarningsAug 06SMA20012.37%Avg Volume1.51MPrice78.98
IPO DateJun 20, 2013Option/ShortYes / YesEPS/Sales Surpr.93.33% 25.81%Net Debt/EBITDA3.67Volume2,849,003Change0.57%
Analyst Ratings
DateActionAnalystRatingTarget
May-27-26UpgradeJefferiesHold → Buy$77 → $85
May-08-26ReiteratedMorgan StanleyOverweight$92 → $94
May-08-26UpgradeTD CowenHold → Buy
Apr-10-26InitiatedRaymond JamesOutperform$108
Mar-30-26DowngradeJefferiesBuy → Hold
Feb-23-26ReiteratedBarclaysOverweight$119 → $120
Feb-23-26ReiteratedMorgan StanleyOverweight$90 → $92
Feb-20-26ReiteratedRBC CapitalSector Perform$91 → $82
Feb-20-26ReiteratedWells FargoOverweight$93 → $86
Jan-28-26UpgradeBarclaysEqual Weight → Overweight$119
Latest News
Jun-15-26
Jun-15-2607:15AM
PTC Therapeutics Announces Proposed Private Placement Of $500M Of Convertible Senior Notes Due 2031Benzinga
Jun-12-26
Jun-12-2608:20AM
PTC THERAPEUTICS INC (NASDAQ:PTCT) Scores Perfect 10/10 For Technical Breakout SetupChartMill
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue8281,731807
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A1837257
Gross Profit6431,659749
Selling, General and Administrative Excl. Other355347301
Research and Development447455534
Other Operating Expense-910217
Operating Income-68857-303
Interest Expense69152167
Unusual Expense
———
Non-Operating Income (Expense)988-106
Net Income Before Taxes-235697-363
Income Taxes-49140
Consolidated Net Income-187683-363
Net Income From Continuing Operations-187683-363
Net Income-187683-363
EPS (Recurring)-2.338.58-4.73
EPS (Basic, Before Extraordinaries)-2.338.58-4.73
EPS (Diluted)-2.337.78-4.73
EBITDA-119888-120
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio—9.76—
Price To Sales Ratio7.923.51—
Gross Margin77.6695.8492.81
Operating Margin-8.2149.51-37.55
Net Margin-22.5839.46-44.98
Shares Outstanding838077
Market Capitalization6,5556,077—
Operating Lease Expense
———
Insider Trading Volume
$88.76$84.35$79.94$75.52$71.11● Close Price0.00M3.10M6.19M9.29M12.39MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Pauwels EricCHIEF BUSINESS OFFICERJun 10 '26Sale46.5135,1321,633,8140Jun 12 12:00 AM
Pauwels EricCHIEF BUSINESS OFFICERJun 10 '26Option Exercise18.0117,566316,36490,977Jun 12 12:00 AM
Boulding Mark ElliottEXEC. VP AND CLOMay 15 '26Option Exercise25.695,624144,480108,024May 19 12:00 AM
Boulding Mark ElliottEXEC. VP AND CLOMay 15 '26Sale72.182,812202,958105,212May 19 12:00 AM
Klein Matthew B.CHIEF EXECUTIVE OFFICERMay 14 '26Sale72.9512,572917,154393,998May 15 12:00 AM
Boulding Mark ElliottEXEC. VP AND CLOMay 08 '26Sale78.973,540279,570105,212May 12 12:00 AM
Boulding Mark ElliottEXEC. VP AND CLOMay 08 '26Option Exercise46.547,080329,504107,952May 12 12:00 AM
Klein Matthew B.CHIEF EXECUTIVE OFFICERApr 21 '26Sale70.912,850202,094394,070Apr 23 12:00 AM
Boulding Mark ElliottEXEC. VP AND CLOApr 06 '26Option Exercise39.424,530178,572107,477Apr 08 12:00 AM
Boulding Mark ElliottEXEC. VP AND CLOApr 06 '26Sale69.452,265157,293105,212Apr 08 12:00 AM
Golden Lee ScottEVP & CHIEF MEDICAL OFFICERApr 02 '26Sale67.9982956,36479,115Apr 06 12:00 AM
Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICERApr 01 '26Sale69.0452,0033,590,24360,137Apr 03 12:00 AM
Klein Matthew B.CHIEF EXECUTIVE OFFICERMar 12 '26Sale64.082,662170,581396,920Mar 13 12:00 AM
Okey StephanieDirectorMar 10 '26Option Exercise33.6329,167980,88622,000Mar 12 12:00 AM
Okey StephanieDirectorMar 10 '26Sale70.0014,000980,0008,000Mar 12 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR